Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | MAP2 | P11137 | 3/20 | 0.38 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | FABP3 | P05413 | 4/20 | 0.36 |
| ▸ | FABP4 | P15090 | 4/20 | 0.36 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL331204 | 0.89 | ADORA2A (0.46) | ADORA2AMAPTLMNAKDM4EALDH1A1 | |
| Acetic Acid SCHEMBL27614844 | 0.73 | CYP2A6 (0.54) | MAPTLMNAFABP3FABP4FABP5 | |
| SCHEMBL29368088 | 0.72 | CYP2A6 (0.44) | MAPTLMNAALDH1A1FABP3FABP4 | |
| SCHEMBL3269166 | 0.72 | CYP2A6 (0.44) | MAPTLMNAALDH1A1FABP3FABP4 | |
| Acetic Acid SCHEMBL3819672 | 0.72 | ALDH1A1 (0.45) | MAPTLMNAKDM4EALDH1A1RECQL | |
| SCHEMBL31607618 | 0.71 | MAOA (0.45) | ADORA2AMAPTLMNAKDM4EALDH1A1 | |
| Acetic Acid SCHEMBL27630446 | 0.71 | CYP2A6 (0.52) | MAPTLMNAFABP3FABP4FABP5 | |
| Acetic Acid SCHEMBL27746609 | 0.71 | CYP2A6 (0.52) | MAPTLMNAFABP3FABP4FABP5 | |
| Acetic Acid SCHEMBL27942328 | 0.71 | DHODH (0.55) | MAPTLMNAFABP3FABP4FABP5 | |
| Acetic Acid SCHEMBL28219393 | 0.71 | CYP2A6 (0.52) | MAPTLMNAFABP3FABP4FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0946170-B8 | DICLOFENAC FOR THE TREATMENT OF VASCULOPATHIES | GLYCADIA INC (US) | 2005-12-07 | — | — | EP | claimed |
| JP-2002515031-A | — | — | 2002-05-21 | — | — | JP | claimed |
| EP-0946170-A4 | INHIBITION OF PROTEIN GLYCATION AND PREVENTION OF VASCULOPATHY | EXOCELL INC (US) | 2002-03-20 | — | — | EP | claimed |
| EP-0946170-A1 | INHIBITION OF PROTEIN GLYCATION AND PREVENTION OF VASCULOPATHY | EXOCELL, INC. (US) | 1999-10-06 | — | — | EP | claimed |
| WO-1997029746-A1 | INHIBITION OF PROTEIN GLYCATION AND PREVENTION OF VASCULOPATHY | EXOCELL, INC. (US) | 1997-08-21 | — | — | WO | claimed |
| US-20240226084-A9 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| US-20240131017-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-04-25 | — | — | US | disclosed |
| US-20240115562-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-04-11 | — | — | US | disclosed |
| US-11857545-B2 | High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-01-02 | — | — | US | disclosed |
| US-9872846-B2 | High penetration compositions and uses thereof | TECHFIELDS PHARMA CO., LTD. (CN) | 2018-01-23 | — | — | US | disclosed |
| US-20170209585-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | TECHFIELDS PHARMA CO LTD (CN) | 2017-07-27 | — | — | US | disclosed |
| US-20170209404-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | PREMIER RESEARCH INTERNATIONAL, LLC | 2017-07-27 | — | — | US | disclosed |
| US-20150072961-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | PREMIER RESEARCH INTERNATIONAL, LLC | 2015-03-12 | — | — | US | disclosed |
| US-20090238763-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | TECHFIELDS PHARMA CO., LTD. (CN) | 2009-09-24 | — | — | US | disclosed |
| EP-0946170-B8 | DICLOFENAC FOR THE TREATMENT OF VASCULOPATHIES | GLYCADIA INC (US) | 2005-12-07 | — | — | EP | disclosed |
| EP-0946170-A4 | INHIBITION OF PROTEIN GLYCATION AND PREVENTION OF VASCULOPATHY | EXOCELL INC (US) | 2002-03-20 | — | — | EP | disclosed |
| EP-0946170-A1 | INHIBITION OF PROTEIN GLYCATION AND PREVENTION OF VASCULOPATHY | EXOCELL, INC. (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1997029746-A1 | INHIBITION OF PROTEIN GLYCATION AND PREVENTION OF VASCULOPATHY | EXOCELL, INC. (US) | 1997-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226084-A9 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | ADORA2A 339/4885HDAC3 1430/4885HDAC1 1829/4885 |
| US-20240115562-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | ADORA2A 339/4885HDAC3 1430/4885HDAC1 1829/4885 |
| US-20150072961-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | ADORA2A 339/4885HDAC3 1430/4885HDAC1 1829/4885 |
| US-20240131017-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | ADORA2A 339/4885HDAC3 1430/4885HDAC1 1829/4885 |
| US-20170209404-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | HPGDS, PTGIS, PTGES | ADORA2A 262/4885HDAC3 1093/4885HDAC1 1392/4885 |
| US-20170209585-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | HPGDS, PTGIS, PTGES | ADORA2A 262/4885HDAC3 1093/4885HDAC1 1392/4885 |
| US-11857545-B2 | High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions | HRH4, HCAR2, PAH | ADORA2A 339/4885HDAC3 1430/4885HDAC1 1829/4885 |
| US-20090238763-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | HPGDS, PTGIS, PTGES | ADORA2A 262/4885HDAC3 1093/4885HDAC1 1392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.